These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 171574)

  • 41. [Extrapancreatic effects of sulfonylurea compounds. 3. Studies on the additional blood sugar decreasing and antilipolytic effect of tolbutamide, glibornuride, and glibenclamide on completely pancreatectomized dogs, chronically treated with insulin during acute experiment and following pretreatment with sulfonylurea compounds using small doses of sulfonylurea].
    Beyer J; Cordes U; Sell G; Schöffling K
    Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2176. PubMed ID: 4198965
    [No Abstract]   [Full Text] [Related]  

  • 42. Studies on the mechanism of action of halofenate.
    Mandel LR
    Lipids; 1977 Jan; 12(1):34-43. PubMed ID: 319318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improved control of non-insulin-dependent diabetes mellitus by combined halofenate and chlorpropamide therapy.
    Kohl EA; Magner JA; Persellin ST; Vaughan GM; Kudzma DJ; Friedberg SJ
    Diabetes Care; 1984; 7(1):19-24. PubMed ID: 6368149
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The interaction between halofenate and propranolol.
    Huffman DH; Azarnoff DL; Shoeman DW; Dujovne CA
    Clin Pharmacol Ther; 1976 Jun; 19(6):807-12. PubMed ID: 773588
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [First clinical experiences in therapy of hyperuricemia and hyperlipidemia with the clofibrate derivative MK 185].
    Wolfram G; Keller C; Kilani C; Zöllner N
    Verh Dtsch Ges Inn Med; 1973; 79():1291-3. PubMed ID: 4597609
    [No Abstract]   [Full Text] [Related]  

  • 47. A comparison of the effects of tolazamide and tolbutamide upon blood glucose and serum insulin and lipid levels in diabetic subjects.
    Moorhouse JA
    Can Med Assoc J; 1967 Mar; 96(9):536-9. PubMed ID: 6019354
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Interference of clofibrate in metabolic compensation in dyslipidemic diabetics].
    Gatti A; Carletta C
    Clin Ter; 1979 Oct; 91(1):57-65. PubMed ID: 397871
    [No Abstract]   [Full Text] [Related]  

  • 49. [Study of oral hypoglycemic agents. VI. Comparative study on acute oral overload using tolbutamide and tolazamide in normal and diabetic subjects. Various aspects of the prolonged use of tolazamide in comparison with other sulfonylureas].
    Pereira VG; Wajchenberg BL; Shnaider J
    Arq Bras Endocrinol Metabol; 1965 Aug; 14(2):133-42. PubMed ID: 5322747
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparative study of several hypolipidemic agents related to clofibrate.
    Beaumont V; Buxtorf JC; Jacotot B; Beaumont JL
    Atherosclerosis; 1974; 20(2):141-53. PubMed ID: 4369878
    [No Abstract]   [Full Text] [Related]  

  • 51. Halofenate and clofibrate: mechanism of hypotriglyceridemic action in the rat.
    Cenedella RJ; Crouthamel WG
    J Lipid Res; 1976 Mar; 17(2):156-66. PubMed ID: 1270931
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Halofenate. Its selection and trial as a primary uricosuric agent.
    Bluestone R; Campion D; Klinenberg JR
    Arthritis Rheum; 1975; 18(6 Suppl):859-62. PubMed ID: 1106434
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of halofenate and clofibrate on lipid synthesis in rat adipocytes.
    Greenspan MD; Germershausen JI; Mackow R
    Biochim Biophys Acta; 1975 Feb; 380(2):190-8. PubMed ID: 1120140
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatic triglyceride lipases--effect of clofibrate and halofenate.
    Cenedella RJ
    Biochem Pharmacol; 1976 Dec; 25(23):2657-61. PubMed ID: 10929
    [No Abstract]   [Full Text] [Related]  

  • 55. [Effects of halofenate on thyroxine-binding globulin (TBG) and thyroid function tests using TBG].
    Miyamoto M; Inoue K; Kojima T; Nagashima N; Ban Y
    Horumon To Rinsho; 1976; 24(3):265-9. PubMed ID: 61080
    [No Abstract]   [Full Text] [Related]  

  • 56. Halofenate, serum lipids, and exercise performance in coronary heart disease.
    Aronow WS; Vangrow JS; Nelson WH; Pagano J; Papageorge's NP; Khursheed M; Harding PR; Khemka M
    Clin Pharmacol Ther; 1974 Jan; 15(1):67-72. PubMed ID: 4587107
    [No Abstract]   [Full Text] [Related]  

  • 57. Effect of halofenate on serum uric acid.
    Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP
    Clin Pharmacol Ther; 1973; 14(3):371-3. PubMed ID: 4572799
    [No Abstract]   [Full Text] [Related]  

  • 58. Effect of halofenate on serum lipids.
    Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP; Mays J
    Clin Pharmacol Ther; 1973; 14(3):358-65. PubMed ID: 4572798
    [No Abstract]   [Full Text] [Related]  

  • 59. Long-term experience with sulfonylureas and placebo.
    Singer DL; Hurwitz D
    N Engl J Med; 1967 Aug; 277(9):450-6. PubMed ID: 5340346
    [No Abstract]   [Full Text] [Related]  

  • 60. Therapy of early diabetes. The University Group Diabetes Program.
    Prout TE
    Adv Metab Disord; 1973; 2():Suppl 2:501-20. PubMed ID: 4720381
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.